Alzheimer’s disease results from the progressive death of brain cells or neurons. Over time the loss of neurons affects processing of information leading to increasingly severe memory loss, disorientation, mood and behavior changes. Are we making any progress on finding a cure for Alzheimer’s disease? Yes, because we now know…
NOT ALL AMYLOID-BETA THERAPEUTICS ARE CREATED EQUAL: PROMIS NEUROSCIENCES LEAD PRODUCT CANDIDATE FOR ALZHEIMER’S DISEASE SHOWS IMPROVED THERAPEUTIC POTENCY VERSUS OTHER AMYLOID BETA-DIRECTED ANTIBODIES Download PDF Humanized PMN310 Shows Significantly Greater Binding to the Toxic Oligomer Fraction from Alzheimer’s Disease Brain Extract Compared to Aducanumab Low molecular weight toxic Aβ…
Selective Targeting Of Toxic Amyloid Beta Oligomers For The Treatment Of Alzheimer’s Disease Johanne Kaplan, Phd from ProMIS™ Neurosciences, Inc. on Vimeo.
October 14th, 2016: ProMIS Chief Development Officer, Dr. Johanne Kaplan, discusses the rationale for the ideal target product profile to address the root cause of Alzheimer’s, Amyloid beta prions.
